153 related articles for article (PubMed ID: 8270432)
1. The hypoxic cytotoxin SR 4233 increases the effectiveness of radioimmunotherapy in mice with human non-Hodgkin's lymphoma xenografts.
Wilder RB; McGann JK; Sutherland WR; Waller EK; Minchinton AI; Goris ML; Knox SJ
Int J Radiat Oncol Biol Phys; 1994 Jan; 28(1):119-26. PubMed ID: 8270432
[TBL] [Abstract][Full Text] [Related]
2. Local hyperthermia and SR 4233 enhance the antitumor effects of radioimmunotherapy in nude mice with human colonic adenocarcinoma xenografts.
Wilder RB; Langmuir VK; Mendonca HL; Goris ML; Knox SJ
Cancer Res; 1993 Jul; 53(13):3022-7. PubMed ID: 8319209
[TBL] [Abstract][Full Text] [Related]
3. Optimizing the use of combined radioimmunotherapy and hypoxic cytotoxin therapy as a function of tumor hypoxia.
Blumenthal RD; Taylor A; Osorio L; Ochakovskaya R; Raleigh JA; Papadopoulou M; Bloomer WD; Goldenberg DM
Int J Cancer; 2001 Nov; 94(4):564-71. PubMed ID: 11745445
[TBL] [Abstract][Full Text] [Related]
4. The combined use of 131I-labeled antibody and the hypoxic cytotoxin SR 4233 in vitro and in vivo.
Langmuir VK; Mendonca HL
Radiat Res; 1992 Dec; 132(3):351-8. PubMed ID: 1475358
[TBL] [Abstract][Full Text] [Related]
5. Radiobiologic studies of radioimmunotherapy and external beam radiotherapy in vitro and in vivo in human renal cell carcinoma xenografts.
Ning S; Trisler K; Wessels BW; Knox SJ
Cancer; 1997 Dec; 80(12 Suppl):2519-28. PubMed ID: 9406705
[TBL] [Abstract][Full Text] [Related]
6. Pretreatment 18F-FAZA PET predicts success of hypoxia-directed radiochemotherapy using tirapazamine.
Beck R; Röper B; Carlsen JM; Huisman MC; Lebschi JA; Andratschke N; Picchio M; Souvatzoglou M; Machulla HJ; Piert M
J Nucl Med; 2007 Jun; 48(6):973-80. PubMed ID: 17536108
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the enhancement of tumor responses to fractionated irradiation by SR 4233 (tirapazamine) and by nicotinamide with carbogen.
Dorie MJ; Menke D; Brown JM
Int J Radiat Oncol Biol Phys; 1994 Jan; 28(1):145-50. PubMed ID: 8270435
[TBL] [Abstract][Full Text] [Related]
8. Preclinical evaluation of 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma.
Chinn PC; Leonard JE; Rosenberg J; Hanna N; Anderson DR
Int J Oncol; 1999 Nov; 15(5):1017-25. PubMed ID: 10536187
[TBL] [Abstract][Full Text] [Related]
9. Radiosensitization of a mouse tumor model by sustained intra-tumoral release of etanidazole and tirapazamine using a biodegradable polymer implant device.
Yapp DT; Lloyd DK; Zhu J; Lehnert S
Radiother Oncol; 1999 Oct; 53(1):77-84. PubMed ID: 10624857
[TBL] [Abstract][Full Text] [Related]
10. Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies.
Ma D; McDevitt MR; Barendswaard E; Lai L; Curcio MJ; Pellegrini V; Brechbiel MW; Scheinberg DA
Leukemia; 2002 Jan; 16(1):60-6. PubMed ID: 11840264
[TBL] [Abstract][Full Text] [Related]
11. Combined modality radioimmunotherapy with Taxol and 90Y-Lym-1 for Raji lymphoma xenografts.
O'Donnell RT; DeNardo SJ; Miers LA; Kukis DL; Mirick GR; Kroger LA; DeNardo GL
Cancer Biother Radiopharm; 1998 Oct; 13(5):351-61. PubMed ID: 10851425
[TBL] [Abstract][Full Text] [Related]
12. Hypoxic sensitizer and cytotoxin for head and neck cancer.
Lee DJ; Moini M; Giuliano J; Westra WH
Ann Acad Med Singap; 1996 May; 25(3):397-404. PubMed ID: 8876907
[TBL] [Abstract][Full Text] [Related]
13. Intratumoral radioimmunotherapy of a human colon cancer xenograft using a sustained-release gel.
Ning S; Trisler K; Brown DM; Yu NY; Kanekal S; Lundsten MJ; Knox SJ
Radiother Oncol; 1996 May; 39(2):179-89. PubMed ID: 8735485
[TBL] [Abstract][Full Text] [Related]
14. Use of 90Y-ibritumomab tiuxetan in non-Hodgkin's lymphoma.
Marcus R
Semin Oncol; 2005 Feb; 32(1 Suppl 1):S36-43. PubMed ID: 15786024
[TBL] [Abstract][Full Text] [Related]
15. A phase I-B trial of the radiosensitizer: etanidazole (SR-2508) with radiosurgery for the treatment of recurrent previously irradiated primary brain tumors or brain metastases (RTOG Study 95-02).
Drzymala RE; Wasserman TH; Won M; Shaw E; Cmelak AJ; Loeffler J; Souhami L;
Radiother Oncol; 2008 Apr; 87(1):89-92. PubMed ID: 18342381
[TBL] [Abstract][Full Text] [Related]
16. Radiation dosimetry for 90Y-2IT-BAD-Lym-1 extrapolated from pharmacokinetics using 111In-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma.
DeNardo GL; O'Donnell RT; Shen S; Kroger LA; Yuan A; Meares CF; Kukis DL; DeNardo SJ
J Nucl Med; 2000 May; 41(5):952-8. PubMed ID: 10809213
[TBL] [Abstract][Full Text] [Related]
17. 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.
Griffiths GL; Govindan SV; Sharkey RM; Fisher DR; Goldenberg DM
J Nucl Med; 2003 Jan; 44(1):77-84. PubMed ID: 12515879
[TBL] [Abstract][Full Text] [Related]
18. Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors.
Brown JM; Lemmon MJ
Cancer Res; 1990 Dec; 50(24):7745-9. PubMed ID: 2253217
[TBL] [Abstract][Full Text] [Related]
19. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
[TBL] [Abstract][Full Text] [Related]
20. Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma.
Ansell SM; Ristow KM; Habermann TM; Wiseman GA; Witzig TE
J Clin Oncol; 2002 Sep; 20(18):3885-90. PubMed ID: 12228209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]